1. A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. (December 2016) Authors: Massard, C.; Soria, J.C.; Stathis, A.; Delord, J.P.; Awada, A.; Peters, S.; Lewin, J.; Bekradda, M.; Rezai, K.; Zeng, Z.; Azher, H.; Perez, S.; Siu, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Are IPL home devices really foolproof?. (24th February 2015) Authors: Schmitt, L.; Rezai, K.; Karsai, S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 5(2016:May) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. (August 2019) Authors: Soussain, C.; Choquet, S.; Blonski, M.; Leclercq, D.; Houillier, C.; Rezai, K.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas-Virelizier, E.; Barrie, M.; Moluçon-Chabrot, C.; Lelez, M.L.; Clavert, A.; Coisy, S.; Leruez, S.; Touitou, V.; Cassoux, N.; Daniau, M. Journal: European journal of cancer Issue: Volume 117(2019) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗